China Biologic Products Inc. (CBPO) Lifted to Buy at Zacks Investment Research
China Biologic Products Inc. (NASDAQ:CBPO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday. The brokerage presently has a $138.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research’s price objective points to a potential upside of 12.03% from the stock’s previous close.
According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
CBPO has been the topic of a number of other research reports. Credit Suisse Group AG upgraded China Biologic Products from a “neutral” rating to an “outperform” rating in a research note on Tuesday, July 5th. Jefferies Group raised their price objective on China Biologic Products from $136.00 to $155.00 and gave the stock a “buy” rating in a research note on Friday, August 5th.
Shares of China Biologic Products (NASDAQ:CBPO) traded up 0.38% during trading on Monday, hitting $123.18. The stock had a trading volume of 76,299 shares. The stock has a 50 day moving average price of $119.06 and a 200-day moving average price of $117.07. China Biologic Products has a one year low of $95.70 and a one year high of $144.29. The stock has a market capitalization of $3.31 billion, a price-to-earnings ratio of 35.52 and a beta of 1.55.
China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $1.26 EPS for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.10. China Biologic Products had a return on equity of 19.65% and a net margin of 29.66%. The firm had revenue of $91.40 million for the quarter, compared to analyst estimates of $87.60 million. During the same quarter last year, the company earned $1.06 EPS. The company’s revenue was up 15.6% on a year-over-year basis. On average, equities research analysts predict that China Biologic Products will post $4.33 earnings per share for the current year.
In other news, CFO Ming Yang sold 21,092 shares of China Biologic Products stock in a transaction on Monday, August 15th. The stock was sold at an average price of $124.32, for a total value of $2,622,157.44. Following the transaction, the chief financial officer now owns 24,782 shares in the company, valued at approximately $3,080,898.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Zhijing Cbpo Liu sold 1,968 shares of China Biologic Products stock in a transaction on Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $244,661.76. The disclosure for this sale can be found here. 2.68% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the stock. Copper Rock Capital Partners LLC raised its position in shares of China Biologic Products by 9.3% in the third quarter. Copper Rock Capital Partners LLC now owns 22,901 shares of the biopharmaceutical company’s stock valued at $2,834,000 after buying an additional 1,941 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of China Biologic Products by 3,357.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,383 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 1,343 shares during the last quarter. Macquarie Group Ltd. acquired a new position in shares of China Biologic Products during the second quarter valued at about $2,721,000. CI Investments Inc. raised its position in shares of China Biologic Products by 13.1% in the second quarter. CI Investments Inc. now owns 65,700 shares of the biopharmaceutical company’s stock valued at $6,985,000 after buying an additional 7,600 shares during the last quarter. Finally, Royal Bank of Canada acquired a new position in shares of China Biologic Products during the second quarter valued at about $9,733,000. Institutional investors own 71.71% of the company’s stock.
China Biologic Products Company Profile
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.